Relatively low-tech and inexpensive to perform, the French Oncotest from Dr Beljanski is a relatively low-tech and inexpensive to perform, the Oncotest methodology was first patented by Dr.Mirko Beljanski and then included in his 1983 work «Regulation of DNA Replication and Transcription» published by Karger.
So, when cancerous DNA was exposed to carcinogenic substances, it replicated rapidly, while non-cancerous DNA replicated only slightly. This could be shown experimentally by adding substances to cancerous DNA or normal DNA and measuring either the increase in growth of the DNA or light absorption of the materials, as the more unstable the DNA, the more light that it would absorb (hyperchromicity (see illustration on the right)). Once carcinogens had destabilized normal DNA to the point that it became permanently destabilized (had become cancerous DNA), further exposure to carcinogens would increase the destabilization, making the cancerous DNA unstable. In other words, cancers cells could become more aggressive and bizarre as they were exposed to more carcinogens.”
These observations resulted in Beljanski developing a test to screen substances for carcinogenicity, which he patented in the 70s as the “Oncotest.” Carcinogens resulted in the rapid replication of cancerous DNA, but affected normal DNA only slightly. Most importantly, the Oncotest revealed that a compound could show carcinogenic properties (by affecting DNA structure) without necessarily being a mutagen, which acts by altering DNA and protein sequences. The Oncotest was ultimately used to test hundreds of compounds for their effect on DNA stability and their potential to act as carcinogens. Relatively low-tech and inexpensive to perform, the Oncotest methodology was first patented by Dr.MirkoBeljanski and then included in his 1983 work «Regulation of DNA Replication and Transcription» published by Karger. (Source)